The patient population in clinical trials is always somewhat selected. Only a well-conducted analysis of real-world clinical practice data can provide a clearer picture of the efficacy and safety of a drug. Therefore, we are currently witnessing a significant development in this type of clinical research, for example, in the form of nationwide cohort studies. How did erlotinib perform in one of them for the treatment of non-small cell lung cancer?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
